Douglas L. Arnold

Research interests

Publications

• How patients with multiple sclerosis acquire disability

  Brain · 2022 · https://doi.org/10.1093/brain/awac016

• Secondary Progressive Multiple Sclerosis

  Neurology · 2021 · https://doi.org/10.1212/wnl.0000000000012323

• Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

  The Lancet Neurology · 2019 · https://doi.org/10.1016/s1474-4422(19)30137-1

• Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial

  The Lancet Neurology · 2019 · https://doi.org/10.1016/s1474-4422(19)30238-8

• Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial

  The Lancet Neurology · 2019 · https://doi.org/10.1016/s1474-4422(19)30239-x

• Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

  The Lancet · 2018 · https://doi.org/10.1016/s0140-6736(18)30475-6

• Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

  The Lancet Neurology · 2018 · https://doi.org/10.1016/s1474-4422(18)30069-3

• Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1800149

• Alemtuzumab CARE-MS II 5-year follow-up

  Neurology · 2017 · https://doi.org/10.1212/wnl.0000000000004354

• Alemtuzumab CARE-MS I 5-year follow-up

  Neurology · 2017 · https://doi.org/10.1212/wnl.0000000000004313

• Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1601277

• Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1606468

• Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1501481

• Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

  The Lancet · 2012 · https://doi.org/10.1016/s0140-6736(12)61768-1

• Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

  The Lancet · 2012 · https://doi.org/10.1016/s0140-6736(12)61769-3

• Review of automatic segmentation methods of multiple sclerosis white matter lesions on conventional magnetic resonance imaging

  Medical Image Analysis · 2012 · https://doi.org/10.1016/j.media.2012.09.004

• Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

  New England Journal of Medicine · 2012 · https://doi.org/10.1056/nejmoa1114287

• Robust Rician noise estimation for MR images

  Medical Image Analysis · 2010 · https://doi.org/10.1016/j.media.2010.03.001

• B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

  New England Journal of Medicine · 2008 · https://doi.org/10.1056/nejmoa0706383

• Imaging of axonal damage in multiple sclerosis: Spatial distribution of magnetic resonance imaging lesions

  Annals of Neurology · 1997 · https://doi.org/10.1002/ana.410410314

• Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy

  Nature Medicine · 1996 · https://doi.org/10.1038/nm0396-323

• Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis

  Annals of Neurology · 1994 · https://doi.org/10.1002/ana.410360115

Current projects

No projects listed.